Seroflo Inhaler: Advanced Dual-Therapy Asthma & COPD Control
| Product dosage: 250mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $110.49 | $110.49 (0%) | 🛒 Add to cart |
| 2 | $94.92 | $220.98 $189.84 (14%) | 🛒 Add to cart |
| 3 | $89.40 | $331.47 $268.19 (19%) | 🛒 Add to cart |
| 4 | $86.63 | $441.96 $346.54 (22%) | 🛒 Add to cart |
| 5 | $85.18 | $552.45 $425.89 (23%) | 🛒 Add to cart |
| 6 | $84.04 | $662.94 $504.23 (24%) | 🛒 Add to cart |
| 7 | $83.37 | $773.43 $583.59 (25%) | 🛒 Add to cart |
| 8 | $82.74
Best per inhaler | $883.92 $661.93 (25%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Seroflo represents a significant advancement in respiratory medicine, combining two proven therapeutic agents into a single, convenient inhaler for the management of asthma and chronic obstructive pulmonary disease (COPD). This fixed-dose combination inhaler synergistically addresses both airway inflammation and bronchoconstriction, the two primary pathological processes in obstructive airway diseases. By delivering a corticosteroid and a long-acting bronchodilator simultaneously, it offers superior symptom control compared to monotherapy, reduces exacerbation frequency, and simplifies treatment regimens, thereby improving adherence and quality of life for patients. Its metered-dose design ensures consistent, precise dosing with each actuation, making it a cornerstone of modern maintenance therapy for moderate to severe persistent asthma and COPD.
Features
- Fixed-dose combination of Fluticasone Propionate (a potent inhaled corticosteroid) and Salmeterol Xinafoate (a long-acting beta2-agonist)
- Available in multiple strength configurations (e.g., Seroflo 100/50, Seroflo 250/50, Seroflo 500/50 mcg per actuation) to allow for individualized dosing
- Delivered via a hydrofluoroalkane (HFA) propellant metered-dose inhaler (MDI)
- Each canister contains 120 metered inhalations
- Incorporates a dose counter to monitor remaining medication
- Designed with a comfortable mouthpiece to facilitate correct inhalation technique
- Requires priming before first use and if not used for a prolonged period
- Stable at room temperature; does not require refrigeration
Benefits
- Provides superior asthma and COPD control by simultaneously reducing airway inflammation and preventing bronchoconstriction
- Significantly reduces the frequency and severity of exacerbations, potentially decreasing the need for oral corticosteroids and hospitalizations
- Simplifies treatment regimens from two separate inhalers to one, enhancing patient compliance and reducing dosing errors
- Improves lung function (FEV1) and overall quality of life by ensuring better day and night-time symptom control
- Offers flexible dosing options to tailor therapy to disease severity and patient response
- The integrated dose counter helps patients track usage and ensures they do not run out of medication unexpectedly
Common use
Seroflo is indicated for the regular maintenance treatment of asthma in patients where a combination product is appropriate: specifically, those not adequately controlled on inhaled corticosteroids and “as needed” short-acting beta2-agonists, or those whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a long-acting beta2-agonist. It is also indicated for the symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with short-acting bronchodilators. It is not intended for the relief of acute bronchospasm.
Dosage and direction
The dosage must be individualized based on disease severity and prior therapy. The inhaler must be shaken well before each use.
Asthma (Adults and Adolescents 12 years and older):
- Recommended starting dose: 2 inhalations twice daily (morning and evening).
- Dosing options: Seroflo 100/50, 250/50, or 500/50. The strength is chosen based on the severity of the asthma and the previous corticosteroid dose.
- The maximum recommended dose is 2 inhalations of Seroflo 500/50 twice daily.
Asthma (Children 4 to 11 years):
- Recommended dose: 2 inhalations of Seroflo 100/50 twice daily.
COPD:
- Recommended dose: 2 inhalations of Seroflo 250/50 twice daily.
Directions for Use:
- Remove the mouthpiece cover. Check the mouthpiece for foreign objects.
- Shake the inhaler well for 5 seconds.
- Breathe out fully, away from the inhaler.
- Place the mouthpiece between your teeth and close your lips around it.
- Just after starting to breathe in slowly and deeply through your mouth, press down firmly on the canister to release the medication.
- Continue to breathe in slowly and deeply.
- Hold your breath for about 10 seconds, or for as long as is comfortable.
- Breathe out slowly.
- Wait about 30 seconds before taking the second inhalation, if prescribed.
- Replace the cap and rinse your mouth with water after use to reduce the risk of oropharyngeal candidiasis and systemic absorption.
Precautions
- Seroflo is not a rescue medication and should not be used to treat acute asthma attacks or acute bronchospasm. Patients must have a separate short-acting beta2-agonist (e.g., salbutamol) inhaler for immediate relief.
- Paradoxical bronchospasm (wheezing immediately after inhalation) may occur. If this happens, treatment should be discontinued immediately and alternative therapy instituted.
- Patients should be advised to seek medical advice if their short-acting reliever inhaler becomes less effective or they need to use it more often than usual, as this is a sign of deteriorating asthma control.
- Systemic effects of inhaled corticosteroids may occur, particularly at high doses and over prolonged periods. These may include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataracts, and glaucoma.
- Be alert to immunosuppression. Potential increase in the risk of infections (e.g., chickenpox, measles) exists. Exposure to such diseases should be avoided; if exposed, medical advice should be sought.
- Use with caution in patients with tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.
- Hypokalemia and hyperglycemia may occur, especially in acute severe asthma, as beta2-agonists can have these effects.
Contraindications
Seroflo is contraindicated in patients with a known hypersensitivity to Fluticasone Propionate, Salmeterol, or any of the excipients in the formulation. It is also contraindicated for the primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required.
Possible side effect
Like all medicines, Seroflo can cause side effects, although not everybody gets them.
Very common (may affect more than 1 in 10 people):
- Headache
Common (may affect up to 1 in 10 people):
- Oropharyngeal candidiasis (thrush)
- Hoarseness, dysphonia
- Throat irritation
- Palpitations
- Tremor
- Muscle cramps
- Cough
Uncommon (may affect up to 1 in 100 people):
- Tachycardia (fast heart rate)
- Skin reactions (rash, urticaria, pruritus)
- Anxiety, sleep disturbances, restlessness
- Nausea
- Bruising
Rare (may affect up to 1 in 1,000 people):
- Cardiac arrhythmias (e.g., atrial fibrillation, supraventricular tachycardia)
- Angioedema
- Anaphylactic reactions
- Increased intraocular pressure, glaucoma
- Cataracts
- Psychiatric effects such as depression, aggression, behavioral changes (primarily in children)
- Hyperglycemia
- Hypokalemia
Drug interaction
- Beta-blockers: Co-administration (including eye drops) may antagonize the bronchodilating effect of Salmeterol and may produce severe bronchospasm in asthmatic patients. Should generally be avoided.
- Diuretics, corticosteroids, xanthine derivatives: May potentiate the hypokalemic effect of beta2-agonists. Serum potassium levels should be monitored in such cases.
- Ketoconazole, Itraconazole, Ritonavir, and other potent CYP3A4 inhibitors: Concomitant use may increase plasma levels of Fluticasone and Salmeterol, increasing the risk of systemic corticosteroid and beta-agonist side effects (e.g., Cushing’s syndrome, adrenal suppression, cardiac effects). Co-administration should be avoided unless the benefit outweighs the increased risk.
- MAOIs and Tricyclic Antidepressants: May potentiate the cardiovascular effects of Salmeterol. Should be administered with extreme caution.
Missed dose
Patients should be instructed to take the next dose at the usual time. They should not take a double dose to make up for a forgotten one. Maintaining a regular schedule is important for optimal control.
Overdose
- Fluticasone Propionate: Acute overdose is unlikely. Chronic overdose may lead to systemic corticosteroid effects such as hypercorticism and adrenal suppression.
- Salmeterol: Overdose may lead to exaggeration of its pharmacologic effects. Expected symptoms include tachycardia, tremor, headache, muscle cramps, palpitations, hypertension, hypokalemia, and hyperglycemia. Cardiac arrest and even death may occur.
- Management: Treatment consists of discontinuation of Seroflo, supportive therapy, and judicious use of a cardioselective beta-blocker if necessary (bearing in mind the risk of inducing bronchospasm in asthmatic patients). Serum potassium levels should be monitored.
Storage
Store at room temperature (below 30°C). Do not puncture, break, or incinerate the canister, even when empty. Keep away from direct sunlight and heat sources. Do not freeze. Keep out of the sight and reach of children. The canister should be discarded 3 months after removal from the foil pouch or when the dose counter reads “0”, whichever comes first.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The brand name “Seroflo” may be a trademark of its respective owner.
Reviews
Clinical studies and meta-analyses consistently demonstrate the efficacy of fluticasone/salmeterol combination therapy. In the GINA (Global Initiative for Asthma) strategy, this combination is a preferred controller option for adults and adolescents with asthma at Step 3 and above. Studies show significantly greater improvements in lung function (FEV1), symptom-free days, and reduced rescue medication use compared to monotherapy with either component alone. For COPD, large trials like TORCH have shown a significant reduction in the rate of exacerbations and a modest improvement in survival compared to placebo. Expert consensus highlights its role in improving adherence and simplifying treatment, which are critical factors in long-term disease management success. Patient-reported outcomes often cite improved ability to perform daily activities and better sleep quality.